

## CLTX CAR T ABSTRACT ACCEPTED FOR PRESENTATION AT ASCO

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company, is pleased to announce the acceptance of the first CLTX CAR T abstract for presentation at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being virtually held from 4-8 June 2021.

Chimeric is pleased that ASCO has selected the abstract for presentation as it highlights City of Hope’s phase 1 clinical trial design and objectives for Chlorotoxin CAR T (CLTX CAR T), a first and potentially best in class CAR T cell therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma. City of Hope, a world- renowned cancer research and treatment center near Los Angeles, is leading the trial.

Details of the abstract presentation are as follows:

**Section:** Trial in Progress: Developmental Therapeutics—Immunotherapy

**Abstract #:** TPS2662

**Title:** *A phase 1 study to evaluate chimeric antigen receptor (CAR) T cells incorporating a chlorotoxin tumor-targeting domain for patients with MMP2+ Recurrent or progressive glioblastoma (NCT04214392). Badie, B., et al.*

Abstract release will be online on May 19, 2021 at 5:00 PM EDT at ASCO.org.

**Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.**

### ABOUT CHLOROTOXIN CAR T

Chlorotoxin CAR T (CLTX CAR T) is a first and potentially best in class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope.

CLTX CAR T cells uniquely utilizes chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumour-targeting component of the chimeric antigen receptor (CAR). CLTX and CLTX CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13.

In preclinical models, CLTX CAR T cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile.

### ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.

Chimeric believes that cellular therapies have the potential to cure cancer and that by combining their expertise in the development and commercialization of cell therapies with the world’s most innovative scientists and science, they will be able to bring the promise of cell therapy to life for more patients.

Chimeric Therapeutics has the exclusive global rights to intellectual property covering the Chlorotoxin CAR T which is currently in development for patients with recurrent glioblastoma and is also being investigated for development in patients with other solid tumors such as melanoma, small cell lung cancer, prostate cancer and colorectal cancer.

Chimeric Therapeutics is also currently actively engaged in enhancing their pipeline with innovative cell therapies for patients with cancer.

## CONTACT

### Investors

Jennifer Chow

Chief Operating Officer

P: 908-723-8387

E: [jchow@chimerictherapeutics.com](mailto:jchow@chimerictherapeutics.com)

### Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)